FASEB J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berdanier, C. D.
Right arrow Articles by McIntosh, M. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berdanier, C. D.
Right arrow Articles by McIntosh, M. K.

The FASEB Journal, Vol 7, 414-419, Copyright © 1993 by The Federation of American Societies for Experimental Biology

REVIEWS

Is dehydroepiandrosterone an antiobesity agent?

CD Berdanier, JA Parente Jr and MK McIntosh
Department of Foods and Nutrition, University of Georgia, Athens 30602- 3622.

The steroid hormone intermediate, DHEA, has been proposed as a therapeutic agent for the treatment of obesity. Its effects on lipogenesis, substrate cycling, peroxisome proliferation, mitochondrial respiration, protein synthesis, and thyroid hormone function have been reported. The results of these studies suggest that the antiobesity function of DHEA is not simply one of inhibiting fat synthesis and deposition but is one of affecting a number of pathways that contribute to the maintenance of the isoenergetic state rather than the promotion of positive energy balance.


This article has been cited by other articles:


Home page
 J. Lipid Res.Home page
C. Lemieux, Y. Gelinas, J. Lalonde, F. Labrie, K. Cianflone, and Y. Deshaies
Hypolipidemic action of the SERM acolbifene is associated with decreased liver MTP and increased SR-BI and LDL receptors
J. Lipid Res., June 1, 2005; 46(6): 1285 - 1294.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
J. M. Abadie, G. T. Malcom, J. R. Porter, and F. Svec
Dehydroepiandrosterone Alters Zucker Rat Soleus and Cardiac Muscle Lipid Profiles
Experimental Biology and Medicine, September 1, 2001; 226(8): 782 - 789.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
A. R. Tagliaferro and A. M. Ronan
Physiological levels and action of dehydroepiandrosterone in Yucatan miniature swine
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2001; 281(1): R1 - R9.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Pritchard, J.-P. Després, J. Gagnon, A. Tchernof, A. Nadeau, A. Tremblay, and C. Bouchard
Plasma Adrenal, Gonadal, and Conjugated Steroids before and after Long Term Overfeeding in Identical Twins
J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3277 - 3284.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. McIntosh, D. Hausman, R. Martin, and G. Hausman
Dehydroepiandrosterone attenuates preadipocyte growth in primary cultures of stromal-vascular cells
Am J Physiol Endocrinol Metab, August 1, 1998; 275(2): E285 - E293.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. A. Benbassat, K. C. Maki, and T. G. Unterman
Circulating Levels of Insulin-Like Growth Factor (IGF) Binding Protein-1 and -3 in Aging Men: Relationships to Insulin, Glucose, IGF, and Dehydroepiandrosterone Sulfate Levels and Anthropometric Measures
J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1484 - 1491.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by The Federation of American Societies for Experimental Biology.